ADMA Biologics Set to Join S&P SmallCap 600 Index

Group 1 - ADMA Biologics, Inc. will join the S&P SmallCap 600 index effective September 23, 2024, which is expected to enhance the company's visibility and share liquidity [1] - The S&P SmallCap 600 index measures the small-cap segment of the U.S. equity market and consists of 600 companies that meet specific inclusion criteria [1] - ADMA Biologics specializes in manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [2] Group 2 - ADMA currently markets three FDA-approved plasma-derived biologics: BIVIGAM®, ASCENIV™, and NABI-HB® for treating immune deficiencies and preventing certain infectious diseases [2] - The company operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, for plasma collection [2] - ADMA holds numerous U.S. and foreign patents related to its products and product candidates, focusing on niche patient populations [2]